Prelude Therapeutics is a clinical-stage precision oncology company headquartered in Wilmington, Delaware. It was incorporated in 2016 and is publicly traded on Nasdaq under the symbol PRLD.
Sana Biotechnology named Brian Piper executive vice president and CFO as it advanced SC451 and SG293. The company reported a fourth-quarter loss of $59 million and cash of $138 million.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer on February 17, 2026. Piper brings over 25 years of biopharmaceutical financial expertise to the cell and gene therapy company.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07469891 |
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms |
RECRUITING | PHASE1 |
| NCT06682806 |
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation |
TERMINATED | PHASE2 |
| NCT06560645 |
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation |
TERMINATED | PHASE1 |
| NCT05665530 |
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies |
COMPLETED | PHASE1 |
| NCT05639751 |
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation |
COMPLETED | PHASE1 |
| NCT05538572 |
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors |
COMPLETED | PHASE1 |
| NCT05159518 |
A Study of PRT2527 in Participants With Advanced Solid Tumors |
COMPLETED | PHASE1 |
| NCT05107856 |
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies |
TERMINATED | PHASE1 |
| NCT04837677 |
A Study of PRT1419 in Patients With Advanced Solid Tumors |
COMPLETED | PHASE1 |
| NCT04543305 |
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies |
COMPLETED | PHASE1 |
